Abstract:Chronic myelogenous leukemia (CML) typically results from a reciprocal translocation between chromosomes 9 and 22 to produce the bcr-abl oncogene that when translated, yields the p210 BCR-ABL protein in more than 90% of all CML patients. This protein has constitutive tyrosine kinase activity that activates numerous downstream pathways that ultimately produces uncontrolled myeloid proliferation. Although the use of the BCR-ABL tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib have increased the overall survival of CML patients, their use is limited by drug resistance and severe adverse effects. Therefore, there is the need to develop novel compounds that can overcome these problems that limit the use of these drugs. Therefore, in this study, we sought to find novel compounds using Hypogen and Hiphip pharmacophore models based on the structures of clinically approved BCR-ABL TKIs. We also used optimal pharmacophore models such as three-dimensional queries to screen the ZINC database to search for potential BCR-ABL inhibitors. The hit compounds were further screened using Lipinski's rule of five, ADMET and molecular docking, and the efficacy of the hit compounds was evaluated. Our in vitro results indicated that compound ZINC21710815 significantly inhibited the proliferation of K562, BaF3/WT, and BaF3/T315I leukemia cells by inducing cell cycle arrest. The compound ZINC21710815 decreased the expression of p-BCR-ABL, STAT5, and Crkl and produced apoptosis and autophagy. Our results suggest that ZINC21710815 may be a potential BCR-ABL inhibitor that should undergo in vivo evaluation.

Discovery of 2,5-Diaminopyrimidine Derivatives As the First Series of Selective Monomeric Degraders of B-lymphoid Tyrosine Kinase

Discovery of Selective Irreversible Inhibitors of B-Lymphoid Tyrosine Kinase (BLK).

Discovery and Biological Evaluation of Pyrimido[4,5-D]pyrimidine-2,4(1h,3h)-dione Derivatives As Potent Bruton’s Tyrosine Kinase Inhibitors

Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degraders with in Vivo Activity.

Discovery and Biological Evaluation of N5-substituted 6,7-Dioxo-6,7-dihydropteridine Derivatives As Potent Bruton's Tyrosine Kinase Inhibitors.

Discovery of Pteridine-7(8H)-one Derivatives As Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK).

Design, Synthesis and Biological Evaluation of Novel 2-Phenyl Pyrimidine Derivatives As Potent Bruton's Tyrosine Kinase (BTK) Inhibitors.

Discovery of Pyrrolo[1,2-A]quinoxalin-4(5h)-one Derivatives As Novel Non-Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies

Design, Synthesis, and Biological Evaluation of Selective TBL1X Degraders

Discovery of Potent and Highly Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Bearing Triazine Scaffold.

Discovery of new BTK inhibitors with B cell suppression activity bearing a 4,6-substituted thieno[3,2-d]pyrimidine scaffold

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.

The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach

Design, Synthesis and Evaluation of Novel 5-Phenylpyridin-2(1h)-one Derivatives As Potent Reversible Bruton's Tyrosine Kinase Inhibitors.

Discovery of New Lenalidomide Derivatives As Potent and Selective GSPT1 Degraders.

Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

Discovery of Pyrazolopyrimidine Derivatives As Potent BTK Inhibitors with Effective Anticancer Activity in MCL.

Discovery of Selective CDK9 Degraders with Enhancing Antiproliferative Activity Through PROTAC Conversion

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.